Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers.
about
Amphetamine, past and present--a pharmacological and clinical perspectiveLisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of EfficacyLong-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challengesA systematic review of the safety of lisdexamfetamine dimesylate.Lisdexamfetamine dimesylate (vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorderAbsorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamineLisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder.Focus on Lisdexamfetamine: A Review of its use in Child and Adolescent Psychiatry.Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases.Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study.Preclinical Assessment of Lisdexamfetamine as an Agonist Medication Candidate for Cocaine Addiction: Effects in Rhesus Monkeys Trained to Discriminate Cocaine or to Self-Administer Cocaine in a Cocaine Versus Food Choice Procedure.Treating attention-deficit/hyperactivity disorder in adults: focus on once-daily medications.Pilot study of the effects of lisdexamfetamine on cocaine use: A randomized, double-blind, placebo-controlled trialDouble-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults.Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate.A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function.Relative Bioavailabilities of Lisdexamfetamine Dimesylate and D-Amphetamine in Healthy Adults in an Open-Label, Randomized, Crossover Study After Mixing Lisdexamfetamine Dimesylate With Food or DrinkLisdexamfetamine in the treatment of adolescents and children with attention-deficit/hyperactivity disorder.Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial.Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD.The use of lisdexamfetamine dimesylate for the treatment of ADHD.Metabolic, toxicological, and safety considerations for drugs used to treat ADHD.An update on lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder.The use of lisdexamfetamine dimesylate for the treatment of ADHD and other psychiatric disorders.Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved indication - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?The safety of extended-release drug formulations for the treatment of ADHD.Lisdexamfetamine: A Review in ADHD in Adults.Metabolism of the prodrug lisdexamfetamine dimesylate in human red blood cells from normal and sickle cell disease donorsPharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with D-Amphetamine in Healthy Subjects.Lisdexamfetamine prodrug activation by peptidase-mediated hydrolysis in the cytosol of red blood cells.Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men.Stimulant 'rapid metabolizers': wrong label, real phenomena.Attention-deficit/hyperactivity disorder
P2860
Q22241826-20B456E6-C28A-430E-B028-38A8CF6BDA92Q26750486-ED417FBB-3735-49A3-B2AD-876831845DA0Q26822392-76AC32D0-A878-475D-8DE6-EB191ECF16A7Q33755396-95C5C56B-F465-4FF9-9BEA-E889145684C2Q33865315-F8EE2E23-EE57-4EA4-A9AB-45BF21C5B4CFQ33966365-143545CB-B56E-474A-9B38-56FDBF53E7D6Q34032634-3D4ADE59-2215-45F3-BB17-6ADE937C97A2Q34232286-5AF55C1F-3381-4268-878B-50DAFD22AD19Q34350145-D60925DE-5AC3-44C2-8A24-2A7BD8BEF6FFQ34518522-14B717FE-C949-45C6-8C2C-C42D55FE8DFBQ35691213-2D1CA90D-DC12-4EEB-BA37-283881066BE2Q35833310-2D7C55F2-1F79-4484-970C-3F6A1511B68EQ35875805-4E5DF019-88F9-4DCD-ACD1-701F14664FA4Q36618017-8AC109E3-868D-4E5C-BF67-4713E2FFE4EFQ36947618-D91D418B-07B6-4899-957C-528AC58B515AQ37104132-EF720B14-280F-4611-A7B2-C8EBC15BD23DQ37506129-33D22BBD-5D9C-4EC8-8DCF-B912DA93A052Q37561623-C015A004-41C7-488B-A1DE-7EA116673777Q37568899-45D778FC-BBD9-4C08-BCF9-CBC9FAEF88FAQ37803420-5410FA9A-3305-421B-A7CF-4F4A4D394C67Q37975550-12E0EC6B-E32A-48DA-9EC9-A6DAB0108AB1Q37993127-39AB2F11-DC21-4747-A1AA-CA9018D24A42Q38067497-BE492D2E-48E7-4CAF-85DB-51CF190E17B9Q38221823-7D921BD7-6B61-4372-A89F-A55936BA8800Q38370764-A7268E42-0F7B-425D-9A9F-92EB0466503BQ38732635-8CE775DE-6000-4DD6-8E4F-CAECDEEC280BQ38799006-F9A28363-202B-49B3-89D1-8ECDDC2F596FQ39478842-2F41A167-039B-4018-AA5D-4836B3AA9B07Q41312831-850F1E61-3EB6-4C7E-B8C6-C24B6F8970EFQ41833735-C5273223-A3B4-4288-95C3-DD7D67CD2C16Q42599423-5A0F71A8-EF02-4759-9335-BC1BACC5F0AEQ47581020-34547035-1AD5-42E5-B0F4-D53E1AE8702BQ56095090-3971DD06-7299-4D68-A813-7E3CF6F33B38
P2860
Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Lisdexamfetamine dimesylate: l ...... y in healthy adult volunteers.
@en
Lisdexamfetamine dimesylate: l ...... y in healthy adult volunteers.
@nl
type
label
Lisdexamfetamine dimesylate: l ...... y in healthy adult volunteers.
@en
Lisdexamfetamine dimesylate: l ...... y in healthy adult volunteers.
@nl
prefLabel
Lisdexamfetamine dimesylate: l ...... y in healthy adult volunteers.
@en
Lisdexamfetamine dimesylate: l ...... y in healthy adult volunteers.
@nl
P2093
P2860
P356
P1476
Lisdexamfetamine dimesylate: l ...... y in healthy adult volunteers.
@en
P2093
Benno Roesch
Jaideep Purkayastha
James Ermer
Mary Buckwalter
Patrick Martin
Robert Homolka
P2860
P304
P356
10.1177/0091270009357346
P577
2010-02-19T00:00:00Z